nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Topoisomerase Inhibitors—Mitoxantrone—multiple sclerosis	0.712	1	CiPCiCtD
Epirubicin—TOP2A—Mitoxantrone—multiple sclerosis	0.0752	0.56	CbGbCtD
Epirubicin—ABCC1—Mitoxantrone—multiple sclerosis	0.0417	0.31	CbGbCtD
Epirubicin—ABCC1—Methotrexate—multiple sclerosis	0.0174	0.129	CbGbCtD
Epirubicin—DHCR7—Vitamin D Metabolism—CYP27B1—multiple sclerosis	0.00469	0.184	CbGpPWpGaD
Epirubicin—DHCR7—Vitamin D Metabolism—CYP24A1—multiple sclerosis	0.00469	0.184	CbGpPWpGaD
Epirubicin—CHD1—brainstem—multiple sclerosis	0.00159	0.0664	CbGeAlD
Epirubicin—DHCR7—Vitamin D Metabolism—VDR—multiple sclerosis	0.00154	0.0601	CbGpPWpGaD
Epirubicin—CHD1—retina—multiple sclerosis	0.00153	0.0641	CbGeAlD
Epirubicin—CHD1—medulla oblongata—multiple sclerosis	0.00111	0.0463	CbGeAlD
Epirubicin—DHCR7—retina—multiple sclerosis	0.00103	0.0432	CbGeAlD
Epirubicin—CHD1—midbrain—multiple sclerosis	0.00101	0.0423	CbGeAlD
Epirubicin—CHD1—spinal cord—multiple sclerosis	0.000989	0.0413	CbGeAlD
Epirubicin—YWHAG—retina—multiple sclerosis	0.000949	0.0396	CbGeAlD
Epirubicin—CHD1—nervous system—multiple sclerosis	0.000833	0.0348	CbGeAlD
Epirubicin—CHD1—central nervous system—multiple sclerosis	0.000802	0.0335	CbGeAlD
Epirubicin—CHD1—cerebellum—multiple sclerosis	0.000784	0.0327	CbGeAlD
Epirubicin—DHCR7—medulla oblongata—multiple sclerosis	0.000748	0.0312	CbGeAlD
Epirubicin—PLA2G4A—phospho-PLA2 pathway—MAPK1—multiple sclerosis	0.000732	0.0287	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—S1PR1—multiple sclerosis	0.000714	0.028	CbGpPWpGaD
Epirubicin—YWHAG—medulla oblongata—multiple sclerosis	0.000686	0.0287	CbGeAlD
Epirubicin—DHCR7—midbrain—multiple sclerosis	0.000683	0.0285	CbGeAlD
Epirubicin—AURKA—nervous system—multiple sclerosis	0.000671	0.0281	CbGeAlD
Epirubicin—DHCR7—spinal cord—multiple sclerosis	0.000667	0.0278	CbGeAlD
Epirubicin—ABCC1—Sphingosine 1-phosphate (S1P) pathway—S1PR1—multiple sclerosis	0.000659	0.0258	CbGpPWpGaD
Epirubicin—AURKA—central nervous system—multiple sclerosis	0.000646	0.027	CbGeAlD
Epirubicin—CHD1—brain—multiple sclerosis	0.000637	0.0266	CbGeAlD
Epirubicin—YWHAG—midbrain—multiple sclerosis	0.000627	0.0262	CbGeAlD
Epirubicin—YWHAG—spinal cord—multiple sclerosis	0.000612	0.0256	CbGeAlD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.000596	0.0234	CbGpPWpGaD
Epirubicin—DHCR7—nervous system—multiple sclerosis	0.000562	0.0235	CbGeAlD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—multiple sclerosis	0.000556	0.278	CbGdCrCtD
Epirubicin—DHCR7—central nervous system—multiple sclerosis	0.000541	0.0226	CbGeAlD
Epirubicin—DHCR7—cerebellum—multiple sclerosis	0.000529	0.0221	CbGeAlD
Epirubicin—YWHAG—nervous system—multiple sclerosis	0.000515	0.0215	CbGeAlD
Epirubicin—AURKA—brain—multiple sclerosis	0.000513	0.0214	CbGeAlD
Epirubicin—PLA2G4A—medulla oblongata—multiple sclerosis	0.000512	0.0214	CbGeAlD
Epirubicin—YWHAG—central nervous system—multiple sclerosis	0.000496	0.0207	CbGeAlD
Epirubicin—YWHAG—cerebellum—multiple sclerosis	0.000485	0.0203	CbGeAlD
Epirubicin—PLA2G4A—midbrain—multiple sclerosis	0.000468	0.0195	CbGeAlD
Epirubicin—PLA2G4A—spinal cord—multiple sclerosis	0.000456	0.0191	CbGeAlD
Epirubicin—DHCR7—brain—multiple sclerosis	0.000429	0.0179	CbGeAlD
Epirubicin—ABCC1—Irinotecan Pathway—BCHE—multiple sclerosis	0.000422	0.0165	CbGpPWpGaD
Epirubicin—YWHAG—brain—multiple sclerosis	0.000394	0.0165	CbGeAlD
Epirubicin—PLA2G4A—nervous system—multiple sclerosis	0.000384	0.0161	CbGeAlD
Epirubicin—PLA2G4A—central nervous system—multiple sclerosis	0.00037	0.0155	CbGeAlD
Epirubicin—AURKA—Floxuridine—Cladribine—multiple sclerosis	0.000363	0.182	CbGdCrCtD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—S1PR1—multiple sclerosis	0.000351	0.0138	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.000335	0.0131	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—S1PR1—multiple sclerosis	0.000327	0.0128	CbGpPWpGaD
Epirubicin—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.000314	0.0123	CbGpPWpGaD
Epirubicin—PLA2G4A—brain—multiple sclerosis	0.000294	0.0123	CbGeAlD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—CBLB—multiple sclerosis	0.000274	0.0107	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—CBLB—multiple sclerosis	0.000274	0.0107	CbGpPWpGaD
Epirubicin—AURKA—Clofarabine—Cladribine—multiple sclerosis	0.000254	0.127	CbGdCrCtD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000248	0.0097	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000246	0.00964	CbGpPWpGaD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—RGS1—multiple sclerosis	0.000241	0.00946	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—RGS1—multiple sclerosis	0.000234	0.00916	CbGpPWpGaD
Epirubicin—ABCC1—cerebellum—multiple sclerosis	0.000207	0.00865	CbGeAlD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—S1PR1—multiple sclerosis	0.000198	0.00776	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000188	0.00735	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000185	0.00725	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000185	0.00725	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—multiple sclerosis	0.000174	0.00681	CbGpPWpGaD
Epirubicin—ABCC1—brain—multiple sclerosis	0.000168	0.00702	CbGeAlD
Epirubicin—UGT2B7—Biological oxidations—CYP27B1—multiple sclerosis	0.000166	0.00652	CbGpPWpGaD
Epirubicin—UGT2B7—Biological oxidations—CYP24A1—multiple sclerosis	0.000166	0.00652	CbGpPWpGaD
Epirubicin—UGT2B7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000164	0.00643	CbGpPWpGaD
Epirubicin—UGT2B7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000164	0.00643	CbGpPWpGaD
Epirubicin—TOP2A—Floxuridine—Cladribine—multiple sclerosis	0.000139	0.0694	CbGdCrCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000131	0.00514	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TNFRSF1A—multiple sclerosis	0.000122	0.00476	CbGpPWpGaD
Epirubicin—PLA2G4A—Glycerophospholipid biosynthesis—BCHE—multiple sclerosis	0.000121	0.00475	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—SRM—multiple sclerosis	0.000117	0.00458	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000114	0.00445	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	0.000109	0.00426	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—MYC—multiple sclerosis	0.000106	0.00416	CbGpPWpGaD
Epirubicin—TOP2A—Clofarabine—Cladribine—multiple sclerosis	9.72e-05	0.0485	CbGdCrCtD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	9.71e-05	0.0038	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—MAPK1—multiple sclerosis	9.66e-05	0.00378	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—MYC—multiple sclerosis	9.64e-05	0.00378	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL10—multiple sclerosis	9.27e-05	0.00363	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—CD58—multiple sclerosis	9.08e-05	0.00356	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SELPLG—multiple sclerosis	9.08e-05	0.00356	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—MERTK—multiple sclerosis	9.08e-05	0.00356	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—BCHE—multiple sclerosis	8.47e-05	0.00332	CbGpPWpGaD
Epirubicin—PLA2G4A—Ca-dependent events—MAPK1—multiple sclerosis	8.39e-05	0.00329	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—FAS—multiple sclerosis	8.35e-05	0.00327	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CYP24A1—multiple sclerosis	8.24e-05	0.00323	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CYP27B1—multiple sclerosis	8.24e-05	0.00323	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	8.05e-05	0.00316	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	7.82e-05	0.00306	CbGpPWpGaD
Epirubicin—PLA2G4A—p38 MAPK Signaling Pathway—MYC—multiple sclerosis	7.76e-05	0.00304	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GPC5—multiple sclerosis	7.54e-05	0.00295	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—STAT3—multiple sclerosis	7.48e-05	0.00293	CbGpPWpGaD
Epirubicin—YWHAG—mTOR signaling pathway—MAPK1—multiple sclerosis	7.37e-05	0.00289	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	7.19e-05	0.00282	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—MAPK1—multiple sclerosis	6.8e-05	0.00266	CbGpPWpGaD
Epirubicin—PLA2G4A—Opioid Signalling—POMC—multiple sclerosis	6.7e-05	0.00263	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	6.46e-05	0.00253	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.26e-05	0.00245	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.26e-05	0.00245	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—RRM1—multiple sclerosis	6.25e-05	0.00245	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	6.23e-05	0.00244	CbGpPWpGaD
Epirubicin—PLA2G4A—PLC beta mediated events—MAPK1—multiple sclerosis	6.18e-05	0.00242	CbGpPWpGaD
Epirubicin—PLA2G4A—G-protein mediated events—MAPK1—multiple sclerosis	6.07e-05	0.00238	CbGpPWpGaD
Epirubicin—TOP2A—Azacitidine—Cladribine—multiple sclerosis	5.93e-05	0.0296	CbGdCrCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.77e-05	0.00226	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PLEK—multiple sclerosis	5.61e-05	0.0022	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—STAT3—multiple sclerosis	5.59e-05	0.00219	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MMP9—multiple sclerosis	5.52e-05	0.00216	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TGFB1—multiple sclerosis	5.31e-05	0.00208	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—STAT3—multiple sclerosis	5.22e-05	0.00204	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	5.13e-05	0.00201	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.12e-05	0.00201	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—MAPK1—multiple sclerosis	5.08e-05	0.00199	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	5.02e-05	0.00196	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.01e-05	0.00196	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.01e-05	0.00196	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5e-05	0.00196	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.94e-05	0.00194	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—STAT3—multiple sclerosis	4.91e-05	0.00192	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL1B—multiple sclerosis	4.88e-05	0.00191	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—STAT3—multiple sclerosis	4.86e-05	0.00191	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	4.86e-05	0.0019	CbGpPWpGaD
Epirubicin—PLA2G4A—Dexamethasone—Methylprednisolone—multiple sclerosis	4.86e-05	0.0243	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Methylprednisolone—multiple sclerosis	4.86e-05	0.0243	CbGdCrCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.85e-05	0.0019	CbGpPWpGaD
Epirubicin—PLA2G4A—Dexamethasone—Betamethasone—multiple sclerosis	4.78e-05	0.0239	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Dexamethasone—multiple sclerosis	4.78e-05	0.0239	CbGdCrCtD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—MAPK1—multiple sclerosis	4.76e-05	0.00186	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—FAS—multiple sclerosis	4.74e-05	0.00186	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—MAPK1—multiple sclerosis	4.74e-05	0.00186	CbGpPWpGaD
Epirubicin—PLA2G4A—Dexamethasone—Triamcinolone—multiple sclerosis	4.67e-05	0.0233	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Triamcinolone—multiple sclerosis	4.67e-05	0.0233	CbGdCrCtD
Epirubicin—PLA2G4A—Endothelins—MAPK1—multiple sclerosis	4.63e-05	0.00182	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—MYC—multiple sclerosis	4.52e-05	0.00177	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MAPK1—multiple sclerosis	4.47e-05	0.00175	CbGpPWpGaD
Epirubicin—PLA2G4A—Betamethasone—Prednisone—multiple sclerosis	4.43e-05	0.0221	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Prednisone—multiple sclerosis	4.43e-05	0.0221	CbGdCrCtD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—MAPK1—multiple sclerosis	4.42e-05	0.00173	CbGpPWpGaD
Epirubicin—PLA2G4A—Betamethasone—Prednisolone—multiple sclerosis	4.33e-05	0.0216	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Prednisolone—multiple sclerosis	4.33e-05	0.0216	CbGdCrCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.28e-05	0.00168	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	4.22e-05	0.00165	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.16e-05	0.00163	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—SRM—multiple sclerosis	4.04e-05	0.00158	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—SRM—multiple sclerosis	3.96e-05	0.00155	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SELE—multiple sclerosis	3.95e-05	0.00155	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.88e-05	0.00152	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.8e-05	0.00149	CbGpPWpGaD
Epirubicin—PLA2G4A—Opioid Signalling—MAPK1—multiple sclerosis	3.79e-05	0.00148	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	3.79e-05	0.00148	CbGpPWpGaD
Epirubicin—UGT2B7—Biological oxidations—POMC—multiple sclerosis	3.74e-05	0.00147	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—S1PR1—multiple sclerosis	3.71e-05	0.00145	CbGpPWpGaD
Epirubicin—TOP2A—Methyltestosterone—Prednisone—multiple sclerosis	3.63e-05	0.0181	CbGdCrCtD
Epirubicin—DHCR7—Metabolism—BCHE—multiple sclerosis	3.59e-05	0.00141	CbGpPWpGaD
Epirubicin—TOP2A—Methyltestosterone—Prednisolone—multiple sclerosis	3.54e-05	0.0177	CbGdCrCtD
Epirubicin—YWHAG—Apoptosis—TNF—multiple sclerosis	3.54e-05	0.00139	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—TNF—multiple sclerosis	3.53e-05	0.00138	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SRM—multiple sclerosis	3.16e-05	0.00124	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—RGS1—multiple sclerosis	3.16e-05	0.00124	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.07e-05	0.0012	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—GPR65—multiple sclerosis	2.99e-05	0.00117	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—MYC—multiple sclerosis	2.97e-05	0.00116	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—STAT3—multiple sclerosis	2.95e-05	0.00115	CbGpPWpGaD
Epirubicin—Tachycardia—Methylprednisolone—multiple sclerosis	2.9e-05	0.000283	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—LINGO1—multiple sclerosis	2.89e-05	0.00113	CbGpPWpGaD
Epirubicin—Skin disorder—Methylprednisolone—multiple sclerosis	2.89e-05	0.000282	CcSEcCtD
Epirubicin—Erythema—Prednisone—multiple sclerosis	2.89e-05	0.000281	CcSEcCtD
Epirubicin—Malnutrition—Prednisone—multiple sclerosis	2.89e-05	0.000281	CcSEcCtD
Epirubicin—Hyperhidrosis—Triamcinolone—multiple sclerosis	2.88e-05	0.000281	CcSEcCtD
Epirubicin—Agranulocytosis—Methotrexate—multiple sclerosis	2.88e-05	0.000281	CcSEcCtD
Epirubicin—Hyperhidrosis—Methylprednisolone—multiple sclerosis	2.88e-05	0.00028	CcSEcCtD
Epirubicin—Convulsion—Betamethasone—multiple sclerosis	2.87e-05	0.00028	CcSEcCtD
Epirubicin—Convulsion—Dexamethasone—multiple sclerosis	2.87e-05	0.00028	CcSEcCtD
Epirubicin—Hypertension—Dexamethasone—multiple sclerosis	2.86e-05	0.000279	CcSEcCtD
Epirubicin—Hypertension—Betamethasone—multiple sclerosis	2.86e-05	0.000279	CcSEcCtD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—multiple sclerosis	2.86e-05	0.00112	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—ITGA4—multiple sclerosis	2.86e-05	0.00112	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL6—multiple sclerosis	2.85e-05	0.00111	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP27B1—multiple sclerosis	2.84e-05	0.00111	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP24A1—multiple sclerosis	2.84e-05	0.00111	CbGpPWpGaD
Epirubicin—Asthenia—Mitoxantrone—multiple sclerosis	2.84e-05	0.000276	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—IFNB1—multiple sclerosis	2.84e-05	0.00111	CbGpPWpGaD
Epirubicin—Myalgia—Dexamethasone—multiple sclerosis	2.82e-05	0.000275	CcSEcCtD
Epirubicin—Myalgia—Betamethasone—multiple sclerosis	2.82e-05	0.000275	CcSEcCtD
Epirubicin—Anxiety—Betamethasone—multiple sclerosis	2.81e-05	0.000274	CcSEcCtD
Epirubicin—Anxiety—Dexamethasone—multiple sclerosis	2.81e-05	0.000274	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—CYP27B1—multiple sclerosis	2.79e-05	0.00109	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP24A1—multiple sclerosis	2.79e-05	0.00109	CbGpPWpGaD
Epirubicin—Discomfort—Dexamethasone—multiple sclerosis	2.79e-05	0.000272	CcSEcCtD
Epirubicin—Discomfort—Betamethasone—multiple sclerosis	2.79e-05	0.000272	CcSEcCtD
Epirubicin—Haemoglobin—Methotrexate—multiple sclerosis	2.79e-05	0.000272	CcSEcCtD
Epirubicin—Hypotension—Methylprednisolone—multiple sclerosis	2.78e-05	0.000271	CcSEcCtD
Epirubicin—Pain—Prednisolone—multiple sclerosis	2.77e-05	0.00027	CcSEcCtD
Epirubicin—Haemorrhage—Methotrexate—multiple sclerosis	2.77e-05	0.00027	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—multiple sclerosis	2.77e-05	0.00027	CcSEcCtD
Epirubicin—Pharyngitis—Methotrexate—multiple sclerosis	2.75e-05	0.000268	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—MYC—multiple sclerosis	2.74e-05	0.00107	CbGpPWpGaD
Epirubicin—Urinary tract disorder—Methotrexate—multiple sclerosis	2.74e-05	0.000267	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—ALB—multiple sclerosis	2.74e-05	0.00107	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CCR1—multiple sclerosis	2.74e-05	0.00107	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL13—multiple sclerosis	2.74e-05	0.00107	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.73e-05	0.00107	CbGpPWpGaD
Epirubicin—Vision blurred—Prednisone—multiple sclerosis	2.72e-05	0.000265	CcSEcCtD
Epirubicin—Urethral disorder—Methotrexate—multiple sclerosis	2.72e-05	0.000265	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	2.72e-05	0.000265	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	2.71e-05	0.000264	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.71e-05	0.00106	CbGpPWpGaD
Epirubicin—Anaphylactic shock—Dexamethasone—multiple sclerosis	2.71e-05	0.000264	CcSEcCtD
Epirubicin—Oedema—Dexamethasone—multiple sclerosis	2.71e-05	0.000264	CcSEcCtD
Epirubicin—Anaphylactic shock—Betamethasone—multiple sclerosis	2.71e-05	0.000264	CcSEcCtD
Epirubicin—Oedema—Betamethasone—multiple sclerosis	2.71e-05	0.000264	CcSEcCtD
Epirubicin—Diarrhoea—Mitoxantrone—multiple sclerosis	2.7e-05	0.000264	CcSEcCtD
Epirubicin—Insomnia—Triamcinolone—multiple sclerosis	2.7e-05	0.000263	CcSEcCtD
Epirubicin—Insomnia—Methylprednisolone—multiple sclerosis	2.69e-05	0.000262	CcSEcCtD
Epirubicin—Infection—Dexamethasone—multiple sclerosis	2.69e-05	0.000262	CcSEcCtD
Epirubicin—Infection—Betamethasone—multiple sclerosis	2.69e-05	0.000262	CcSEcCtD
Epirubicin—Ill-defined disorder—Prednisone—multiple sclerosis	2.68e-05	0.000261	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—MAPK1—multiple sclerosis	2.68e-05	0.00105	CbGpPWpGaD
Epirubicin—Paraesthesia—Triamcinolone—multiple sclerosis	2.68e-05	0.000261	CcSEcCtD
Epirubicin—Feeling abnormal—Prednisolone—multiple sclerosis	2.67e-05	0.000261	CcSEcCtD
Epirubicin—Paraesthesia—Methylprednisolone—multiple sclerosis	2.67e-05	0.00026	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—multiple sclerosis	2.67e-05	0.00026	CcSEcCtD
Epirubicin—Anaemia—Prednisone—multiple sclerosis	2.67e-05	0.00026	CcSEcCtD
Epirubicin—Shock—Betamethasone—multiple sclerosis	2.66e-05	0.00026	CcSEcCtD
Epirubicin—Shock—Dexamethasone—multiple sclerosis	2.66e-05	0.00026	CcSEcCtD
Epirubicin—Dyspnoea—Triamcinolone—multiple sclerosis	2.66e-05	0.000259	CcSEcCtD
Epirubicin—Nervous system disorder—Dexamethasone—multiple sclerosis	2.65e-05	0.000259	CcSEcCtD
Epirubicin—Nervous system disorder—Betamethasone—multiple sclerosis	2.65e-05	0.000259	CcSEcCtD
Epirubicin—Agitation—Prednisone—multiple sclerosis	2.65e-05	0.000259	CcSEcCtD
Epirubicin—Thrombocytopenia—Dexamethasone—multiple sclerosis	2.65e-05	0.000258	CcSEcCtD
Epirubicin—Thrombocytopenia—Betamethasone—multiple sclerosis	2.65e-05	0.000258	CcSEcCtD
Epirubicin—Tachycardia—Dexamethasone—multiple sclerosis	2.64e-05	0.000257	CcSEcCtD
Epirubicin—Tachycardia—Betamethasone—multiple sclerosis	2.64e-05	0.000257	CcSEcCtD
Epirubicin—Dyspepsia—Triamcinolone—multiple sclerosis	2.63e-05	0.000256	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—multiple sclerosis	2.62e-05	0.000255	CcSEcCtD
Epirubicin—Dyspepsia—Methylprednisolone—multiple sclerosis	2.62e-05	0.000255	CcSEcCtD
Epirubicin—Hyperhidrosis—Dexamethasone—multiple sclerosis	2.62e-05	0.000255	CcSEcCtD
Epirubicin—Hyperhidrosis—Betamethasone—multiple sclerosis	2.62e-05	0.000255	CcSEcCtD
Epirubicin—Malaise—Prednisone—multiple sclerosis	2.6e-05	0.000254	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—GPC5—multiple sclerosis	2.6e-05	0.00102	CbGpPWpGaD
Epirubicin—Vertigo—Prednisone—multiple sclerosis	2.59e-05	0.000253	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—multiple sclerosis	2.59e-05	0.000253	CcSEcCtD
Epirubicin—Syncope—Prednisone—multiple sclerosis	2.59e-05	0.000252	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—multiple sclerosis	2.58e-05	0.000252	CcSEcCtD
Epirubicin—Anorexia—Dexamethasone—multiple sclerosis	2.58e-05	0.000251	CcSEcCtD
Epirubicin—Anorexia—Betamethasone—multiple sclerosis	2.58e-05	0.000251	CcSEcCtD
Epirubicin—Urticaria—Prednisolone—multiple sclerosis	2.58e-05	0.000251	CcSEcCtD
Epirubicin—Cardiac disorder—Methotrexate—multiple sclerosis	2.57e-05	0.000251	CcSEcCtD
Epirubicin—Fatigue—Triamcinolone—multiple sclerosis	2.57e-05	0.000251	CcSEcCtD
Epirubicin—Fatigue—Methylprednisolone—multiple sclerosis	2.57e-05	0.00025	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GPC5—multiple sclerosis	2.55e-05	0.000999	CbGpPWpGaD
Epirubicin—Pain—Triamcinolone—multiple sclerosis	2.55e-05	0.000249	CcSEcCtD
Epirubicin—Loss of consciousness—Prednisone—multiple sclerosis	2.54e-05	0.000247	CcSEcCtD
Epirubicin—Hypotension—Betamethasone—multiple sclerosis	2.53e-05	0.000246	CcSEcCtD
Epirubicin—Hypotension—Dexamethasone—multiple sclerosis	2.53e-05	0.000246	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—multiple sclerosis	2.52e-05	0.000245	CcSEcCtD
Epirubicin—Vomiting—Mitoxantrone—multiple sclerosis	2.51e-05	0.000245	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—TAGAP—multiple sclerosis	2.51e-05	0.000983	CbGpPWpGaD
Epirubicin—Immune system disorder—Methotrexate—multiple sclerosis	2.5e-05	0.000244	CcSEcCtD
Epirubicin—Convulsion—Prednisone—multiple sclerosis	2.5e-05	0.000244	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—multiple sclerosis	2.5e-05	0.000244	CcSEcCtD
Epirubicin—Hypertension—Prednisone—multiple sclerosis	2.49e-05	0.000243	CcSEcCtD
Epirubicin—Rash—Mitoxantrone—multiple sclerosis	2.49e-05	0.000243	CcSEcCtD
Epirubicin—Dermatitis—Mitoxantrone—multiple sclerosis	2.49e-05	0.000243	CcSEcCtD
Epirubicin—Chills—Methotrexate—multiple sclerosis	2.49e-05	0.000242	CcSEcCtD
Epirubicin—Headache—Mitoxantrone—multiple sclerosis	2.48e-05	0.000241	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	2.47e-05	0.00024	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	2.47e-05	0.00024	CcSEcCtD
Epirubicin—UGT2B7—NRF2 pathway—TGFB1—multiple sclerosis	2.46e-05	0.000964	CbGpPWpGaD
Epirubicin—Myalgia—Prednisone—multiple sclerosis	2.46e-05	0.00024	CcSEcCtD
Epirubicin—Arthralgia—Prednisone—multiple sclerosis	2.46e-05	0.00024	CcSEcCtD
Epirubicin—Feeling abnormal—Triamcinolone—multiple sclerosis	2.46e-05	0.00024	CcSEcCtD
Epirubicin—Feeling abnormal—Methylprednisolone—multiple sclerosis	2.45e-05	0.000239	CcSEcCtD
Epirubicin—Anxiety—Prednisone—multiple sclerosis	2.45e-05	0.000239	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—multiple sclerosis	2.45e-05	0.000239	CcSEcCtD
Epirubicin—Insomnia—Dexamethasone—multiple sclerosis	2.45e-05	0.000239	CcSEcCtD
Epirubicin—Insomnia—Betamethasone—multiple sclerosis	2.45e-05	0.000239	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	2.44e-05	0.000238	CcSEcCtD
Epirubicin—ABCC1—Disease—GPC5—multiple sclerosis	2.43e-05	0.000954	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	2.43e-05	0.000237	CcSEcCtD
Epirubicin—Paraesthesia—Betamethasone—multiple sclerosis	2.43e-05	0.000237	CcSEcCtD
Epirubicin—Paraesthesia—Dexamethasone—multiple sclerosis	2.43e-05	0.000237	CcSEcCtD
Epirubicin—Discomfort—Prednisone—multiple sclerosis	2.43e-05	0.000237	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—multiple sclerosis	2.43e-05	0.000237	CcSEcCtD
Epirubicin—Erythema—Methotrexate—multiple sclerosis	2.41e-05	0.000235	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—multiple sclerosis	2.41e-05	0.000235	CcSEcCtD
Epirubicin—Hypersensitivity—Prednisolone—multiple sclerosis	2.39e-05	0.000233	CcSEcCtD
Epirubicin—Dyspepsia—Dexamethasone—multiple sclerosis	2.38e-05	0.000232	CcSEcCtD
Epirubicin—Dyspepsia—Betamethasone—multiple sclerosis	2.38e-05	0.000232	CcSEcCtD
Epirubicin—Urticaria—Triamcinolone—multiple sclerosis	2.37e-05	0.000231	CcSEcCtD
Epirubicin—Urticaria—Methylprednisolone—multiple sclerosis	2.36e-05	0.00023	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—multiple sclerosis	2.36e-05	0.00023	CcSEcCtD
Epirubicin—Body temperature increased—Triamcinolone—multiple sclerosis	2.36e-05	0.00023	CcSEcCtD
Epirubicin—Anaphylactic shock—Prednisone—multiple sclerosis	2.36e-05	0.00023	CcSEcCtD
Epirubicin—Oedema—Prednisone—multiple sclerosis	2.36e-05	0.00023	CcSEcCtD
Epirubicin—Abdominal pain—Methylprednisolone—multiple sclerosis	2.35e-05	0.000229	CcSEcCtD
Epirubicin—Decreased appetite—Betamethasone—multiple sclerosis	2.35e-05	0.000229	CcSEcCtD
Epirubicin—Decreased appetite—Dexamethasone—multiple sclerosis	2.35e-05	0.000229	CcSEcCtD
Epirubicin—Nausea—Mitoxantrone—multiple sclerosis	2.35e-05	0.000229	CcSEcCtD
Epirubicin—Infection—Prednisone—multiple sclerosis	2.34e-05	0.000228	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Betamethasone—multiple sclerosis	2.34e-05	0.000228	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	2.34e-05	0.000228	CcSEcCtD
Epirubicin—Back pain—Methotrexate—multiple sclerosis	2.33e-05	0.000228	CcSEcCtD
Epirubicin—Fatigue—Dexamethasone—multiple sclerosis	2.33e-05	0.000227	CcSEcCtD
Epirubicin—Fatigue—Betamethasone—multiple sclerosis	2.33e-05	0.000227	CcSEcCtD
Epirubicin—Shock—Prednisone—multiple sclerosis	2.32e-05	0.000226	CcSEcCtD
Epirubicin—Pain—Betamethasone—multiple sclerosis	2.31e-05	0.000226	CcSEcCtD
Epirubicin—Pain—Dexamethasone—multiple sclerosis	2.31e-05	0.000226	CcSEcCtD
Epirubicin—Nervous system disorder—Prednisone—multiple sclerosis	2.31e-05	0.000225	CcSEcCtD
Epirubicin—Tachycardia—Prednisone—multiple sclerosis	2.3e-05	0.000224	CcSEcCtD
Epirubicin—Skin disorder—Prednisone—multiple sclerosis	2.29e-05	0.000223	CcSEcCtD
Epirubicin—Hyperhidrosis—Prednisone—multiple sclerosis	2.28e-05	0.000222	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—multiple sclerosis	2.27e-05	0.000222	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.25e-05	0.000882	CbGpPWpGaD
Epirubicin—Anorexia—Prednisone—multiple sclerosis	2.25e-05	0.000219	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.25e-05	0.00088	CbGpPWpGaD
Epirubicin—Ill-defined disorder—Methotrexate—multiple sclerosis	2.24e-05	0.000218	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—multiple sclerosis	2.23e-05	0.000217	CcSEcCtD
Epirubicin—Feeling abnormal—Betamethasone—multiple sclerosis	2.23e-05	0.000217	CcSEcCtD
Epirubicin—Feeling abnormal—Dexamethasone—multiple sclerosis	2.23e-05	0.000217	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYP27B1—multiple sclerosis	2.23e-05	0.000873	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP24A1—multiple sclerosis	2.23e-05	0.000873	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.22e-05	0.00087	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Betamethasone—multiple sclerosis	2.21e-05	0.000216	CcSEcCtD
Epirubicin—Gastrointestinal pain—Dexamethasone—multiple sclerosis	2.21e-05	0.000216	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.2e-05	0.000863	CbGpPWpGaD
Epirubicin—Hypersensitivity—Triamcinolone—multiple sclerosis	2.2e-05	0.000214	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—S1PR1—multiple sclerosis	2.19e-05	0.000859	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methylprednisolone—multiple sclerosis	2.19e-05	0.000214	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.18e-05	0.000853	CbGpPWpGaD
Epirubicin—Malaise—Methotrexate—multiple sclerosis	2.18e-05	0.000212	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—multiple sclerosis	2.17e-05	0.000211	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—multiple sclerosis	2.16e-05	0.000211	CcSEcCtD
Epirubicin—DHCR7—Metabolism—APOE—multiple sclerosis	2.16e-05	0.000845	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—RRM1—multiple sclerosis	2.16e-05	0.000844	CbGpPWpGaD
Epirubicin—Urticaria—Dexamethasone—multiple sclerosis	2.15e-05	0.00021	CcSEcCtD
Epirubicin—Urticaria—Betamethasone—multiple sclerosis	2.15e-05	0.00021	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Prednisone—multiple sclerosis	2.15e-05	0.000209	CcSEcCtD
Epirubicin—Dizziness—Prednisolone—multiple sclerosis	2.14e-05	0.000209	CcSEcCtD
Epirubicin—Asthenia—Triamcinolone—multiple sclerosis	2.14e-05	0.000209	CcSEcCtD
Epirubicin—Abdominal pain—Dexamethasone—multiple sclerosis	2.14e-05	0.000209	CcSEcCtD
Epirubicin—Abdominal pain—Betamethasone—multiple sclerosis	2.14e-05	0.000209	CcSEcCtD
Epirubicin—Body temperature increased—Dexamethasone—multiple sclerosis	2.14e-05	0.000209	CcSEcCtD
Epirubicin—Body temperature increased—Betamethasone—multiple sclerosis	2.14e-05	0.000209	CcSEcCtD
Epirubicin—Asthenia—Methylprednisolone—multiple sclerosis	2.14e-05	0.000208	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—GPC5—multiple sclerosis	2.13e-05	0.000836	CbGpPWpGaD
Epirubicin—Insomnia—Prednisone—multiple sclerosis	2.13e-05	0.000208	CcSEcCtD
Epirubicin—Paraesthesia—Prednisone—multiple sclerosis	2.12e-05	0.000206	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—RRM1—multiple sclerosis	2.11e-05	0.000828	CbGpPWpGaD
Epirubicin—Pruritus—Triamcinolone—multiple sclerosis	2.11e-05	0.000206	CcSEcCtD
Epirubicin—Cough—Methotrexate—multiple sclerosis	2.11e-05	0.000205	CcSEcCtD
Epirubicin—Pruritus—Methylprednisolone—multiple sclerosis	2.11e-05	0.000205	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.1e-05	0.000822	CbGpPWpGaD
Epirubicin—Convulsion—Methotrexate—multiple sclerosis	2.09e-05	0.000204	CcSEcCtD
Epirubicin—Dyspepsia—Prednisone—multiple sclerosis	2.07e-05	0.000202	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—MYC—multiple sclerosis	2.06e-05	0.000806	CbGpPWpGaD
Epirubicin—Myalgia—Methotrexate—multiple sclerosis	2.05e-05	0.0002	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—multiple sclerosis	2.05e-05	0.0002	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—multiple sclerosis	2.05e-05	0.0002	CcSEcCtD
Epirubicin—Decreased appetite—Prednisone—multiple sclerosis	2.05e-05	0.0002	CcSEcCtD
Epirubicin—Rash—Prednisolone—multiple sclerosis	2.04e-05	0.000199	CcSEcCtD
Epirubicin—Dermatitis—Prednisolone—multiple sclerosis	2.04e-05	0.000199	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	2.04e-05	0.000199	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GPC5—multiple sclerosis	2.04e-05	0.000799	CbGpPWpGaD
Epirubicin—Diarrhoea—Methylprednisolone—multiple sclerosis	2.04e-05	0.000198	CcSEcCtD
Epirubicin—Fatigue—Prednisone—multiple sclerosis	2.03e-05	0.000198	CcSEcCtD
Epirubicin—Headache—Prednisolone—multiple sclerosis	2.03e-05	0.000198	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—multiple sclerosis	2.03e-05	0.000198	CcSEcCtD
Epirubicin—Constipation—Prednisone—multiple sclerosis	2.02e-05	0.000196	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	2.01e-05	0.000788	CbGpPWpGaD
Epirubicin—Confusional state—Methotrexate—multiple sclerosis	1.99e-05	0.000194	CcSEcCtD
Epirubicin—Dizziness—Triamcinolone—multiple sclerosis	1.97e-05	0.000192	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—multiple sclerosis	1.97e-05	0.000192	CcSEcCtD
Epirubicin—Dizziness—Methylprednisolone—multiple sclerosis	1.97e-05	0.000192	CcSEcCtD
Epirubicin—Infection—Methotrexate—multiple sclerosis	1.96e-05	0.000191	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—IL2RA—multiple sclerosis	1.95e-05	0.000765	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.95e-05	0.000764	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CCL3—multiple sclerosis	1.95e-05	0.000764	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.95e-05	0.000762	CbGpPWpGaD
Epirubicin—Feeling abnormal—Prednisone—multiple sclerosis	1.94e-05	0.000189	CcSEcCtD
Epirubicin—Asthenia—Dexamethasone—multiple sclerosis	1.94e-05	0.000189	CcSEcCtD
Epirubicin—Asthenia—Betamethasone—multiple sclerosis	1.94e-05	0.000189	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—multiple sclerosis	1.93e-05	0.000188	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—multiple sclerosis	1.93e-05	0.000188	CcSEcCtD
Epirubicin—Gastrointestinal pain—Prednisone—multiple sclerosis	1.93e-05	0.000188	CcSEcCtD
Epirubicin—Nausea—Prednisolone—multiple sclerosis	1.93e-05	0.000188	CcSEcCtD
Epirubicin—Pruritus—Betamethasone—multiple sclerosis	1.91e-05	0.000187	CcSEcCtD
Epirubicin—Pruritus—Dexamethasone—multiple sclerosis	1.91e-05	0.000187	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—multiple sclerosis	1.91e-05	0.000186	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.91e-05	0.000747	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Methotrexate—multiple sclerosis	1.9e-05	0.000186	CcSEcCtD
Epirubicin—Vomiting—Triamcinolone—multiple sclerosis	1.9e-05	0.000185	CcSEcCtD
Epirubicin—Vomiting—Methylprednisolone—multiple sclerosis	1.89e-05	0.000184	CcSEcCtD
Epirubicin—Rash—Triamcinolone—multiple sclerosis	1.88e-05	0.000183	CcSEcCtD
Epirubicin—Dermatitis—Triamcinolone—multiple sclerosis	1.88e-05	0.000183	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—multiple sclerosis	1.88e-05	0.000183	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PTGER4—multiple sclerosis	1.88e-05	0.000735	CbGpPWpGaD
Epirubicin—Rash—Methylprednisolone—multiple sclerosis	1.88e-05	0.000183	CcSEcCtD
Epirubicin—Dermatitis—Methylprednisolone—multiple sclerosis	1.87e-05	0.000183	CcSEcCtD
Epirubicin—Urticaria—Prednisone—multiple sclerosis	1.87e-05	0.000182	CcSEcCtD
Epirubicin—Headache—Triamcinolone—multiple sclerosis	1.87e-05	0.000182	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—RGS1—multiple sclerosis	1.86e-05	0.00073	CbGpPWpGaD
Epirubicin—Headache—Methylprednisolone—multiple sclerosis	1.86e-05	0.000182	CcSEcCtD
Epirubicin—Abdominal pain—Prednisone—multiple sclerosis	1.86e-05	0.000182	CcSEcCtD
Epirubicin—Body temperature increased—Prednisone—multiple sclerosis	1.86e-05	0.000182	CcSEcCtD
Epirubicin—DHCR7—Metabolism—POMC—multiple sclerosis	1.85e-05	0.000726	CbGpPWpGaD
Epirubicin—Diarrhoea—Dexamethasone—multiple sclerosis	1.85e-05	0.00018	CcSEcCtD
Epirubicin—Diarrhoea—Betamethasone—multiple sclerosis	1.85e-05	0.00018	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—multiple sclerosis	1.84e-05	0.000179	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MYC—multiple sclerosis	1.84e-05	0.00072	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.82e-05	0.000712	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCR3—multiple sclerosis	1.81e-05	0.00071	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—MAPK1—multiple sclerosis	1.8e-05	0.000705	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	1.79e-05	0.000175	CcSEcCtD
Epirubicin—Dizziness—Dexamethasone—multiple sclerosis	1.79e-05	0.000174	CcSEcCtD
Epirubicin—Dizziness—Betamethasone—multiple sclerosis	1.79e-05	0.000174	CcSEcCtD
Epirubicin—Insomnia—Methotrexate—multiple sclerosis	1.78e-05	0.000174	CcSEcCtD
Epirubicin—Nausea—Triamcinolone—multiple sclerosis	1.77e-05	0.000173	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—multiple sclerosis	1.77e-05	0.000172	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—GPR65—multiple sclerosis	1.77e-05	0.000692	CbGpPWpGaD
Epirubicin—Nausea—Methylprednisolone—multiple sclerosis	1.77e-05	0.000172	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CCR2—multiple sclerosis	1.76e-05	0.000691	CbGpPWpGaD
Epirubicin—Dyspnoea—Methotrexate—multiple sclerosis	1.76e-05	0.000171	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—multiple sclerosis	1.75e-05	0.000171	CcSEcCtD
Epirubicin—Hypersensitivity—Prednisone—multiple sclerosis	1.74e-05	0.000169	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—multiple sclerosis	1.73e-05	0.000169	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.73e-05	0.000678	CbGpPWpGaD
Epirubicin—Vomiting—Dexamethasone—multiple sclerosis	1.72e-05	0.000168	CcSEcCtD
Epirubicin—Vomiting—Betamethasone—multiple sclerosis	1.72e-05	0.000168	CcSEcCtD
Epirubicin—Decreased appetite—Methotrexate—multiple sclerosis	1.71e-05	0.000167	CcSEcCtD
Epirubicin—Rash—Betamethasone—multiple sclerosis	1.71e-05	0.000166	CcSEcCtD
Epirubicin—Rash—Dexamethasone—multiple sclerosis	1.71e-05	0.000166	CcSEcCtD
Epirubicin—Dermatitis—Dexamethasone—multiple sclerosis	1.7e-05	0.000166	CcSEcCtD
Epirubicin—Dermatitis—Betamethasone—multiple sclerosis	1.7e-05	0.000166	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—multiple sclerosis	1.7e-05	0.000166	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.7e-05	0.000665	CbGpPWpGaD
Epirubicin—Fatigue—Methotrexate—multiple sclerosis	1.7e-05	0.000166	CcSEcCtD
Epirubicin—Headache—Betamethasone—multiple sclerosis	1.7e-05	0.000165	CcSEcCtD
Epirubicin—Headache—Dexamethasone—multiple sclerosis	1.7e-05	0.000165	CcSEcCtD
Epirubicin—Asthenia—Prednisone—multiple sclerosis	1.69e-05	0.000165	CcSEcCtD
Epirubicin—DHCR7—Metabolism—ALB—multiple sclerosis	1.69e-05	0.000662	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—RRM1—multiple sclerosis	1.69e-05	0.000662	CbGpPWpGaD
Epirubicin—Pain—Methotrexate—multiple sclerosis	1.68e-05	0.000164	CcSEcCtD
Epirubicin—Pruritus—Prednisone—multiple sclerosis	1.67e-05	0.000163	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.64e-05	0.000642	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CNR1—multiple sclerosis	1.63e-05	0.000638	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—IL6—multiple sclerosis	1.63e-05	0.000637	CbGpPWpGaD
Epirubicin—Feeling abnormal—Methotrexate—multiple sclerosis	1.62e-05	0.000158	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL13—multiple sclerosis	1.62e-05	0.000633	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCR1—multiple sclerosis	1.62e-05	0.000633	CbGpPWpGaD
Epirubicin—Diarrhoea—Prednisone—multiple sclerosis	1.61e-05	0.000157	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—multiple sclerosis	1.61e-05	0.000157	CcSEcCtD
Epirubicin—Nausea—Betamethasone—multiple sclerosis	1.61e-05	0.000157	CcSEcCtD
Epirubicin—Nausea—Dexamethasone—multiple sclerosis	1.61e-05	0.000157	CcSEcCtD
Epirubicin—ABCC1—Disease—RPL5—multiple sclerosis	1.58e-05	0.00062	CbGpPWpGaD
Epirubicin—Urticaria—Methotrexate—multiple sclerosis	1.56e-05	0.000153	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MYC—multiple sclerosis	1.56e-05	0.000611	CbGpPWpGaD
Epirubicin—Dizziness—Prednisone—multiple sclerosis	1.56e-05	0.000152	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—multiple sclerosis	1.56e-05	0.000152	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—multiple sclerosis	1.56e-05	0.000152	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	1.52e-05	0.000597	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SLC11A1—multiple sclerosis	1.52e-05	0.000594	CbGpPWpGaD
Epirubicin—Vomiting—Prednisone—multiple sclerosis	1.5e-05	0.000146	CcSEcCtD
Epirubicin—Rash—Prednisone—multiple sclerosis	1.49e-05	0.000145	CcSEcCtD
Epirubicin—Dermatitis—Prednisone—multiple sclerosis	1.48e-05	0.000145	CcSEcCtD
Epirubicin—Headache—Prednisone—multiple sclerosis	1.48e-05	0.000144	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL10—multiple sclerosis	1.47e-05	0.000574	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methotrexate—multiple sclerosis	1.45e-05	0.000141	CcSEcCtD
Epirubicin—Asthenia—Methotrexate—multiple sclerosis	1.41e-05	0.000138	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—ALB—multiple sclerosis	1.41e-05	0.000553	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.41e-05	0.000552	CbGpPWpGaD
Epirubicin—Nausea—Prednisone—multiple sclerosis	1.4e-05	0.000136	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MYC—multiple sclerosis	1.39e-05	0.000546	CbGpPWpGaD
Epirubicin—Pruritus—Methotrexate—multiple sclerosis	1.39e-05	0.000136	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MAPK1—multiple sclerosis	1.36e-05	0.000534	CbGpPWpGaD
Epirubicin—Diarrhoea—Methotrexate—multiple sclerosis	1.35e-05	0.000131	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.31e-05	0.000513	CbGpPWpGaD
Epirubicin—Dizziness—Methotrexate—multiple sclerosis	1.3e-05	0.000127	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.28e-05	0.000503	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CCL5—multiple sclerosis	1.26e-05	0.000494	CbGpPWpGaD
Epirubicin—Vomiting—Methotrexate—multiple sclerosis	1.25e-05	0.000122	CcSEcCtD
Epirubicin—Rash—Methotrexate—multiple sclerosis	1.24e-05	0.000121	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—multiple sclerosis	1.24e-05	0.000121	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—BCHE—multiple sclerosis	1.24e-05	0.000485	CbGpPWpGaD
Epirubicin—Headache—Methotrexate—multiple sclerosis	1.23e-05	0.00012	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—BCHE—multiple sclerosis	1.21e-05	0.000476	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD28—multiple sclerosis	1.21e-05	0.000474	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—multiple sclerosis	1.17e-05	0.000114	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CCL3—multiple sclerosis	1.15e-05	0.000451	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—IL2—multiple sclerosis	1.14e-05	0.000448	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CCR5—multiple sclerosis	1.14e-05	0.000445	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.13e-05	0.000441	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2RA—multiple sclerosis	1.12e-05	0.000439	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTGER4—multiple sclerosis	1.11e-05	0.000434	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PGR—multiple sclerosis	1.09e-05	0.000428	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—multiple sclerosis	1.09e-05	0.000427	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCR3—multiple sclerosis	1.07e-05	0.00042	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	1.07e-05	0.000418	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CD28—multiple sclerosis	1.06e-05	0.000416	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCR2—multiple sclerosis	1.04e-05	0.000408	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.03e-05	0.000402	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.76e-06	0.000382	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—multiple sclerosis	9.75e-06	0.000382	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—BCHE—multiple sclerosis	9.7e-06	0.00038	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CNR1—multiple sclerosis	9.62e-06	0.000377	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MAPK1—multiple sclerosis	9.54e-06	0.000374	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TGFB1—multiple sclerosis	8.93e-06	0.00035	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—POMC—multiple sclerosis	8.88e-06	0.000348	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—MAPK1—multiple sclerosis	8.75e-06	0.000343	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CCL2—multiple sclerosis	8.69e-06	0.00034	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL10—multiple sclerosis	8.66e-06	0.000339	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD86—multiple sclerosis	8.64e-06	0.000338	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—TYK2—multiple sclerosis	7.89e-06	0.000309	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CCR5—multiple sclerosis	7.66e-06	0.0003	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CD86—multiple sclerosis	7.57e-06	0.000297	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HLA-A—multiple sclerosis	7.47e-06	0.000292	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCL5—multiple sclerosis	7.45e-06	0.000292	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—APOE—multiple sclerosis	7.45e-06	0.000292	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—APOE—multiple sclerosis	7.31e-06	0.000286	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APOE—multiple sclerosis	6.97e-06	0.000273	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SPP1—multiple sclerosis	6.9e-06	0.00027	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCR5—multiple sclerosis	6.71e-06	0.000263	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2RA—multiple sclerosis	6.62e-06	0.000259	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—multiple sclerosis	6.57e-06	0.000257	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—POMC—multiple sclerosis	6.4e-06	0.000251	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD80—multiple sclerosis	6.3e-06	0.000247	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—POMC—multiple sclerosis	6.28e-06	0.000246	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APOE—multiple sclerosis	6.11e-06	0.000239	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—APOE—multiple sclerosis	5.84e-06	0.000229	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ALB—multiple sclerosis	5.83e-06	0.000229	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ALB—multiple sclerosis	5.72e-06	0.000224	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CD80—multiple sclerosis	5.52e-06	0.000216	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TYK2—multiple sclerosis	5.32e-06	0.000208	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—POMC—multiple sclerosis	5.25e-06	0.000206	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCL2—multiple sclerosis	5.13e-06	0.000201	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAPK1—multiple sclerosis	5.02e-06	0.000197	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—POMC—multiple sclerosis	5.01e-06	0.000196	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD4—multiple sclerosis	4.81e-06	0.000188	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TYK2—multiple sclerosis	4.66e-06	0.000183	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ALB—multiple sclerosis	4.57e-06	0.000179	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—multiple sclerosis	3.88e-06	0.000152	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—multiple sclerosis	3.86e-06	0.000151	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—multiple sclerosis	3.72e-06	0.000146	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—multiple sclerosis	3.67e-06	0.000144	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—multiple sclerosis	3.46e-06	0.000136	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFB1—multiple sclerosis	3.45e-06	0.000135	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAPK1—multiple sclerosis	3.39e-06	0.000133	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—multiple sclerosis	3.26e-06	0.000128	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—multiple sclerosis	3.03e-06	0.000119	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFB1—multiple sclerosis	3.03e-06	0.000119	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK1—multiple sclerosis	2.97e-06	0.000116	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—multiple sclerosis	2.6e-06	0.000102	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—multiple sclerosis	2.28e-06	8.93e-05	CbGpPWpGaD
